Company Description
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome.
It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials.
The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes.
It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies.
The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018.
Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
| Country | United States |
| IPO Date | Dec 4, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 147 |
| CEO | Dr. Omid C. Farokhzad M.D., Ph.D. |
Contact Details
Address: 3800 Bridge Parkway Redwood City, California United States | |
| Website | https://seer.bio |
Stock Details
| Ticker Symbol | SEER |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001726445 |
| CUSIP Number | 81578P106 |
| ISIN Number | US81578P1066 |
| Employer ID | 82-1153150 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Dr. Omid C. Farokhzad M.D., Ph.D. | Founder, Chief Executive Officer, & Chair of the Board of Directors |
| David R. Horn | President,Treasurer & Chief Financial Officer |
| Joe Laws | Chief Technology Officer and Co-Founder |
| Marissa Dixon | Chief People Officer |
| Dr. Asim Siddiqui Ph.D. | Senior Vice President of Research & Tech Development |
| Dr. Serafim Batzoglou Ph.D. | Chief Data Officer |
| Kenny Ross | Chief Operations & Product Officer |
| Martin Goldberg Ph.D. | Senior Vice President of Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 08, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Nov 06, 2024 | 10-Q | Quarterly Report |
| Nov 06, 2024 | 8-K | Current Report |
| Oct 07, 2024 | 4 | Filing |
| Oct 07, 2024 | 4 | Filing |
| Oct 07, 2024 | 8-K | Current Report |
| Aug 16, 2024 | 8-K | Current Report |
| Aug 15, 2024 | 4 | Filing |
| Aug 15, 2024 | 3 | Filing |
| Aug 08, 2024 | 10-Q | Quarterly Report |